Bring The full potential of our innovative medicines to patients

Build

A high-value sustainable pipeline

Deliver

Efficiencies to enable targeted investment & growth

Q1 2023 sales update

27 April 2023



Focus. Together. For patients & society

A culture of collaboration & excellence

Boost

Disclaimer and safe harbor

- This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management's current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated in the summary information. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably given that a new medicine can appear to be promising at a preparatory stage of development or after clinical trials but never be launched on the market or be launched on the market but fail to sell notably for regulatory or competitive reasons. Ipsen must deal with or may have to deal with competition from generic medicines that may result in market-share losses, which could affect its level of growth in sales or profitability. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this presentation to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law.
- All medicine names listed in this document are either licensed to Ipsen or are registered trademarks of Ipsen or its partners.
- The implementation of the strategy has to be submitted to the relevant staff representation authorities in each country concerned, in compliance with the specific procedures, terms and conditions set forth by each national legislation.
- In those countries in which public or private-health cover is provided, Ipsen is dependent on prices set for medicines, pricing and reimbursement-regime reforms and is vulnerable to the potential withdrawal of certain medicines from the list of reimbursable medicines by governments, and the relevant regulatory authorities in its locations.
- Ipsen operates in certain geographical regions whose governmental finances, local currencies or inflation rates could erode the local competitiveness of Ipsen's medicines relative to competitors operating in local currency, and/or could be detrimental to Ipsen's margins in those regions where Ipsen's sales are billed in local currencies.
- In a number of countries, Ipsen markets its medicines via distributors or agents; some of these partners' financial strengths could be impacted by changing economic or market conditions, potentially subjecting Ipsen to difficulties in recovering its receivables. Furthermore, in certain countries whose financial equilibrium is threatened by changing economic or market conditions, and where Ipsen sells its medicines directly to hospitals, Ipsen could be forced to lengthen its payment terms or could experience difficulties in recovering its receivables in full.
- Ipsen also faces various risks and uncertainties inherent to its activities identified under the caption 'Risk Factors' in the Company's Universal Registration Document.
- All of the above risks could affect lpsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today.



Speakers



David Loew Chief Executive Officer

For Q&A Aymeric Le Chatelier Chief Financial Officer



Highlights

Consistent strong delivery on the strategic roadmap

Total sales

- Q1 sales growth of 5.7%
- Growth platforms, up by 14.7%, led by Dysport & Cabometyx
- Contribution from newly acquired medicines

Albireo

- Albireo acquisition completed in March
- One month of Bylvay sales in Q1



Pipeline update

- Onivyde 1L PDAC
 Full Phase III data presented
- Forthcoming PDUFA dates:
 - 15 June: Bylvay (Alagille syndrome)
 - 16 August: palovarotene (FOP)

2023 guidance confirmed

- Total-sales growth greater than 4.0%¹
- Core operating margin around 30%²

All growth rates are at constant exchange rates.

¹ Excludes adverse impact of around 2% from currencies based on the average level of exchange rates in Q1 2023.

^{2.} Excludes any potential impact of incremental investments from external-innovation transactions.

Growth platforms: Dysport, Decapeptyl, Cabometyx and Onivyde; 1L: first line; PDAC: pancreatic ductal adenocarcinoma;

PDUFA: Prescription Drug User Fee Act; **FOP**: fibrodysplasia ossificans progressiva.




Sales highlights

Growth platforms outweighing the gradual decline of Somatuline

	Q1 2023		
	€m	change	% of total sales
Dysport	155	25.2%	21%
Cabometyx	130	31.0%	18%
Decapeptyl	130	0.8%	17%
Onivyde	37	-12.3%	5%
Growth platforms	452	14.7%	61%
Tazverik	9	n/a	1%
Bylvay	5	n/a	1%
Newly acquired medicines	14	n/a	2%
Somatuline	263	-9.8%	35%
Others	13	-20.8%	2%
Total Sales	742	5.7%	100%



Strong performance from growth platforms of +14.7%






Somatuline sales continuing to decline gradually



Q1 2023: -9.8%





All growth rates are at constant exchange rates. In this presentation, Europe is defined as the E.U., the U.K., Iceland, Liechtenstein, Norway and Switzerland.

Recently acquired medicines





€9m

Momentum in North America and Europe

€5m

An increasing number of treated PFIC patients

Anticipated regulatory decisions this year in Alagille syndrome

Growth of 21% in commercial sales¹

Focus on all-comers, new-patient starts & duration of therapy

NCCN guidelines recently updated



All growth rates are at constant exchange rates. ¹ Reference to Epizyme's published Q1 2022 performance. **PFIC**: progressive familial intrahepatic cholestasis; **NCCN**: National Comprehensive Cancer Network.

Building a high-value, sustainable pipeline





Information shown as at the end of March 2023. **R/R**: relapsed/refractory; **DLBCL**: diffuse large B-cell lymphoma; **Tx**: therapeutics; **mCRPC**: metastatic castration-resistant prostate cancer; **FOP**: fibrodysplasia ossificans progressiva; **PSC**: primary sclerosing cholangitis; **Ax**: aesthetics; **2L**: second line; **1L**: first line; **PDAC**: pancreatic ductal adenocarcinoma; **R**²: lenalidomide + rituximab; **FL**: follicular lymphoma; **PBC**: primary biliary cholangitis.

Pipeline: near-term major milestones

Bylvay: Alagille syndrome

PDUFA date: 15 June 2023 (U.S.) Regulatory decision: H2 2023 (E.U.)

Onivyde: 1L PDAC

Regulatory submission (U.S.): H1 2023

Elafibranor: 2L PBC

Phase III data readout: end of H1 2023

Palovarotene: FOP

PDUFA date: 16 August 2023 (U.S.) Re-examination of CHMP opinion requested (E.U.)¹

Cabometyx + atezolizumab: 2L mCRPC

Phase III data readout (PFS): H2 2023




^{1.} Negative opinion published in January 2023. PDUFA: Prescription Drug User Fee Act; 1L: first line; PDAC: pancreatic ductal adenocarcinoma; 2L: second line; PBC: primary biliary cholangitis; FOP: fibrodysplasia ossificans progressiva; CHMP: the Committee for Medicinal Products for Human Use, the European Medicines Agency's committee responsible for human medicines; mCRPC: metastatic castration-resistant prostate cancer; PFS: progression-free survival.



Conclusion

Consistent strong delivery on the strategic roadmap



A strong Q1 sales performance Double-digit increase in the growth platforms Financial guidance for 2023 confirmed

Expanding the scope in Rare Disease The integration of Albireo

Building a high-value, sustainable pipeline

Several near-term milestones External-innovation focus continues




QUESTIONS

APPENDIX



Q1 2023 total sales: favorable 2.1% impact of fx rates



Average rate changes



Oncology

Key ongoing clinical-trial highlights

TRIAL	POPULATION	PATIENTS	DESIGN	PRIMARY ENDPOINT(S)	STATUS
Cabometyx CONTACT-02 Phase III NCT04446117	2L mCRPC	580	Second novel hormonal therapy (abiraterone & prednisone or enzalutamide) or Cabometyx + atezolizumab	OS, PFS	Recruiting ¹ PFS data anticipated H2 2023
Onivyde NAPOLI-3 Phase III NCT04083235	1L PDAC	770	Nab-paclitaxel + gemcitabine or Onivyde + 5-FU/LV + oxaliplatin	OS	Primary endpoint met
Tazverik SYMPHONY-1 Phase III NCT04224493	R/R FL: following at least one prior systemic chemotherapy, immunotherapy, or chemo- immunotherapy	540	Placebo + R ² or Tazverik + R ²	PFS	Recruiting



Recruitment is anticipated to complete in H2 2023. 2L: second line; mCRPC: metastatic castration-resistant prostate cancer; OS: overall survival; PFS: progression-free survival; 1L: first line; PDAC: pancreatic ductal adenocarcinoma; R/R: relapsed/refractory; FL: follicular lymphoma; R²: lenalidomide + rituximab.

Oncology

Key ongoing clinical-trial highlights

TRIAL	POPULATION	PATIENTS	DESIGN	PRIMARY ENDPOINT(S)	STATUS
Tazverik ARIA Phase Ib/II NCT05205252	R/R hematologic malignancies	156	Tazverik in various combinations: multi- cohort	Phase Ib: dosing, safety Phase II: ORR	Recruiting
IPN60210 Phase I/Ib NCT05121103	R/R multiple myeloma & R/R DLBCL	96	IPN60210	Treatment-emergent adverse events, dosing & ORR	Recruiting
Tazverik CELLO-1 Phase Ib/II NCT04179864	mCRPC: patients who have not received chemotherapy	104	Enzalutamide + Tazverik or abiraterone/prednisone + Tazverik	Phase Ib: dosing, safety Phase II: rPFS Tazverik + enzalutamide	Recruiting



R/R: relapsed/refractory; **ORR**: objective response rate; **DLBCL**: diffuse large B-cell lymphoma; **mCRPC**: metastatic castration-resistant prostate cancer; **rPFS**: radiographic progression-free survival.

Rare Disease

Key ongoing clinical-trial highlights

TRIAL	POPULATION	PATIENTS	DESIGN	PRIMARY ENDPOINT	STATUS
Elafibranor ELATIVE Phase III NCT04526665	2L PBC	161	Placebo or elafibranor	Response to treatment defined as ALP < 1.67 x ULN and total bilirubin ≤ ULN and ALP decrease ≥ 15 percent	Data anticipated H1 2023
Bylvay ASSERT Phase III NCT04674761	Alagille syndrome	63	Placebo or Bylvay	Change from baseline in scratching score	U.S. PDUFA date 15 June 2023 E.U. regulatory decision anticipated in H2 2023
Bylvay BOLD Phase III	Biliary atresia	205	Placebo or Bylvay	Proportion of patients who are alive and have not undergone a liver transplant after 104 weeks of study treatment	Recruiting



2L: second line; PBC: primary biliary cholangitis; ALP: alkaline phosphatase; ULN: upper limit normal; PDUFA: Prescription Drug User Fee Act.

Rare Disease

Key ongoing clinical-trial highlights

TRIAL	POPULATION	PATIENTS	DESIGN	PRIMARY ENDPOINT(S)	STATUS
Palovarotene MOVE Phase III NCT03312634	FOP (chronic)	107	Palovarotene - 5mg QD and upon flare-up, 20mg QD for 28 days, followed by 10mg for 56 days	Annualized change in new HO volume	U.S.: PDUFA date 16 August 2023 E.U. CHMP: negative opinion January 2023 - re-examination requested
Fidrisertib FALKON Phase II NCT05039515	FOP (chronic)	90	Placebo or two dosing regimens of fidrisertib	Annualized change in new HO volume and safety	First patient commenced dosing Q1 2022



FOP: fibrodysplasia ossificans progressiva; **QD**: once a day; **HO**: heterotopic ossification; **PDUFA**: Prescription Drug User Fee Act; **CHMP**: the Committee for Medicinal Products for Human Use, the European Medicines Agency's committee responsible for human medicines.

Rare Disease

Key ongoing clinical-trial highlights

TRIAL	POPULATION	PATIENTS	DESIGN	PRIMARY ENDPOINT(S)	STATUS
IPN60250 (A3907) Phase II NCT05642468	Primary sclerosing cholangitis	12	10mg IPN60250 tablet QD for 12 weeks 30mg (3x10 mg) IPN60250 tablets QD for 12 weeks	Treatment-related adverse events	Recruiting
Elafibranor ELMWOOD Phase II NCT05627362	Primary sclerosing cholangitis	60	Placebo or elafibranor	Safety, significant changes in physical examination findings, laboratory parameters, vital signs, electrocardiogram readings	Recruiting
IPN60260 (A2342) Phase I ISRCTN13265717	Viral cholestatic disease	108	Interventional	To be confirmed	Recruiting



Neuroscience

Key ongoing clinical-trial highlights

TRIAL	POPULATION	PATIENTS	DESIGN	PRIMARY ENDPOINT	STATUS
IPN10200 Ax LANTIC Phase II NCT04821089	Moderate to severe upper facial lines	424	Dose escalation & dose finding versus Dysport or placebo	Safety	First patient commenced dosing Q1 2023
IPN10200 Tx LANTIMA Phase I/II NCT04752774	Adult patients with upper limb spasticity	209	Dose escalation & dose finding versus Dysport or placebo	Safety	Recruiting



^{1.} Good 'ON-time' is the time that people living with Parkinson's disease experience improved Parkinsonian symptoms and no dyskinesia.



Investor Relations



Nicolas BOGLER Investor Relations Senior Manager © +33 6 52 19 98 92 © nicolas.bogler@ipsen.com

V





Follow us www.ipsen.com

